Advertisement

Immunotherapy of Melanoma

  • Lynn E. Spitler
  • Charles Scott

Abstract

Are there tumor-associated transplantation antigens (TATAs) on human tumor cells? If there are, are human subjects capable of mounting an immune response to those TATAs? Does clinical malignancy develop because of a failure of the normal immunological response to the tumor? The answers to these very basic questions of tumor immunology are unknown at present, and it seems unlikely that they will be answered in the near future.

Keywords

Transfer Factor Bacillus Calmette Guerin Intratumoral Injection Superficial Bladder Cancer Melanoma Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bast, R. C., Jr., Zbar, B., Borsos, T., and Rapp, H. J., 1974, BCG and cancer (second of two parts), N. Engl. J. Med. 290: 1458–1469.PubMedCrossRefGoogle Scholar
  2. Beretta, G., 1980, Randomized study of prolonged chemotherapy, immunotherapy, and chemoimmunotherapy as an adjuvant for Stage I and II malignant melama (trial 6 ), Presented at the Second International Conference on the Immunotherapy of Cancer: Present Status of Trials in Man, Bethesda, Maryland, April 28–30.Google Scholar
  3. Borden, E. C., Crowley, J., Davis, T. E., and Wolberg, W. H., 1980, Levamisole: Effects in primary and recurrent colorectal carcinoma, Presented at the Second International Conference on the Immunotherapy of Cancer: Present Status of Trials in Man, Bethesda, Maryland, April 28–30.Google Scholar
  4. Bucana, C., and Hanna, M. G., Jr., 1974, Immunoelectronmicroscopic analysis of surface antigens common to Mycobacterium bonis(BCG) and tumor cells, J. Natl. Cancer Inst. 53: 1313–1323.PubMedGoogle Scholar
  5. Camacho, F., Pinsky, C., Kerr, D., Whitmore, W., and Oettgen, H., 1980, Treatment of superficial bladder cancer with intravesical BCG, Presented at the Second International Conference on the Immunotherapy of Cancer: Present Status of Trials in Man, Bethesda, Maryland, April 28–30.Google Scholar
  6. Cunningham, T. J., Schoenfeld, D., Nathanson, L., Wolter, J., Patterson, W. B., and Borden, E., 1980, A controlled ECOG study of adjuvant therapy (BCG, BCG-DTIC) in patients with stage I and II malignant melanoma, Presented at the Second International Conference on the Immunotherapy of Cancer; Present Status of Trials in Man, Bethesda, Maryland, April 28–30.Google Scholar
  7. Eilber, R. F., Morton, D. L. Holmes, E. C., Sparks, F. C., and Ramming, K. P., 1976, Adjuvant immunotherapy with BCG in treatment of regional-lymph node metastases from malignant melanoma, N. Engl. J. Med. 294: 237–240.PubMedCrossRefGoogle Scholar
  8. Gonzales, R. L., Wong, P., and Spitler, L. E., 1980, Adjuvant immunotherapy with transfer factor in patients with melanoma metastatic to lung, Cancer 45: 57–63.CrossRefGoogle Scholar
  9. Gutterman, J. U., Mavligit, G., Gottlieb, J. A., Burgess, M. A., McBride, C. E., Einhorn, L., Freireich, E. J., and Hersh, E. M., 1974, Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus Calmette-Guerin, N. Engl. J. Med. 291: 592–595.PubMedCrossRefGoogle Scholar
  10. Gutterman, J. U., Mavligit, G. M., McBride, C. M., Richman, S. P., Burgess, M. A., and Hersh, E. M., 1978, Postoperative immunotherapy for recurrent malignant melanoma: An updated report, in: Immunotherapy of Cancer: Present Status of Trials in Man( W. D. Terry and D. Windhorst, eds.), pp. 35–55, Raven Press, New York.Google Scholar
  11. Lamm, D. L., Thor, D. E., Harris, S. C., Stogdill, V. D., and Radwin, H. M., 1980, Intravesical and percutaneous BCG immunotherapy of recurrent superficial bladder cancer, Presented at the Second International Conference on the Immunotherapy of Cancer: Present Status of Trials in Man, Bethesda, Maryland, April 28–30.Google Scholar
  12. Lawrence, H. S., 1980, The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leukocytes, J. Clin. Invest. 34: 219–230.CrossRefGoogle Scholar
  13. Levin, A. S., Byers, V. S., Fudenberg, H. H., Wybran, J., Hackett, A. J., Johnston, J. O., and Spitler, L. E., 1975, Osteogenic sarcoma: Immunologic parameters before and during immunotherapy with tumor-specific transfer factor, J. Clin. Invest. 55: 487–499.PubMedCrossRefGoogle Scholar
  14. Little, J. H., 1971, Partial regression in primary cutaneous malignant melanoma, Pathology 3: 62.Google Scholar
  15. Lowe, J., Iles, P. B., Shore, D. F., Langman, M. J. S., and Baldwin, R. W., 1980, Intrapleural BCG in operable lung cancer, Lancet 2: 11–14.CrossRefGoogle Scholar
  16. McGovern, V. J., 1972, Melanoma: Growth patterns, multiplicity and regression, in: Melanoma and Skin Cancer( W. H. McCarthy, ed.), pp. 95–106, VCN Blight, Government Printer, Sydney, Australia.Google Scholar
  17. McKahn, C. F., Hendrickson, C. G., Spitler, L. E., Gunnarsson, A., Banerjee, D., and Nelson, W. R., 1975, Immunotherapy of melanoma with BCG: Two fatalities following intralesional injection, Cancer 35: 514–520.CrossRefGoogle Scholar
  18. McKneally, M. F., Mayer, C., and Kausel, H. W., 1976, Regional immunotherapy of lung cancer with intra-pleural B.C.G., Lancet 2: 377–379.CrossRefGoogle Scholar
  19. Morales, A., and Ersil, A., 1980, Prophylaxis and treatment of non-infiltrating bladder cancer with BCG, Presented at the Second International Conference on the Immunotherapy Cancer: Present Status of Trials in Man, Bethesda, Maryland, April 28–30.Google Scholar
  20. Morton, D. L., 1974, BCG immunotherapy of malignant melanoma: Summary of a seven-year experience, Surgery 180: 635–643.Google Scholar
  21. Morton, D. L., 1980, Adjuvant immunotherapy of malignant melanoma: Results of a randomized trial, Presented at the Second International Conference on the Immunotherapy of Cancer: Present Status of Trials in Man, Bethesda, Maryland, April 28–30.Google Scholar
  22. Pinsky, C. M., Hirshaut, Y., and Wanebo, H. J., 1976, Randomized trial of bacillus Calmette-Guerin (per-cutaneous administration) as surgical adjuvant immunotherapy for patients with Stage II melanoma, Ann. N.Y. Acad. Sci. 277: 187–192.PubMedCrossRefGoogle Scholar
  23. Renoux, G., and Renoux, M., 1972, Action immunostimulante de derives du phenylimidothiazide sur les cellules spleniques formatrices d’anticorps, C. R. Acad. Sci. Ser. D 274: 756–757.Google Scholar
  24. Rojas, A. F., Mickiewicz, E., Feierstein, J. N., Glait, H., and Olivari, A. J., 1976, Levamisole in advanced human breast cancer, Lancet 1: 211–215.PubMedCrossRefGoogle Scholar
  25. Salmon, S. E., Alexanian, R., and Dixon, D., 1980, Chemoimmunotherapy for multiple myeloma: Effect of levamisole, Presented at the Second International Conference on the Immunotherapy of Cancer: Present Status of Trials in Man, Bethesda, Maryland, April 28–30.Google Scholar
  26. Spitler, L. E., 1978, Transfer factor, in: Handbook Series in Clinical Laboratory Science, Section F: Immunology, Vol. 1, Part 1 ( A. Baumgarten and F. F. Richards, eds.), pp. 87–106, CRC Press, West Palm Beach, Floria.Google Scholar
  27. Spitler, L. E., 1980, BCG, levamisole, and transfer factor in the treatment of cancer, Prog. Exp. Tumor Res. 25: 178–192.PubMedGoogle Scholar
  28. Spitler, L. E., and Sagebiel, R., 1980, A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma, N. Engl. J. Med. 303: 1143–1147.PubMedCrossRefGoogle Scholar
  29. Terry, W. D., Hodes, R. J., and Rosenberg, S. A., 1980, Treatment of stage I and II malignant melanoma with adjuvant immunotherapy or chemotherapy: Preliminary anylysis of a prospective, randomized trial, Presented at the Second International Conference on the Immunotherapy of Cancer: Present Status of Trials in Man, Bethesda, Maryland, April 28–30.Google Scholar
  30. Tripodi, D., Parks, L. C., and Brugmans, J., 1973, Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer, N. Engl. J. Med. 289: 354–357.PubMedCrossRefGoogle Scholar
  31. Verhaegen, H., DeCree, J., DeCock, W., and Verhaegen-Declercq, M. L., 1980, Levamisole therapy in patients with colorectal cancer, Presented at the Second International Conference on the Immunotherapy of Cancer: Present Status of Trials in Man, Bethesda, Maryland, April 28–30.Google Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Lynn E. Spitler
    • 1
  • Charles Scott
    • 1
  1. 1.Paul M. Aggeler Memorial Laboratory, Department of MedicineChildren’s Hospital, University of California Medical CenterSan FranciscoUSA

Personalised recommendations